MCID: DRM010
MIFTS: 65

Dermatomyositis

Categories: Rare diseases, Skin diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Muscle diseases

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 12 72 49 50 55 51 41 14 69
Amyopathic Dermatomyositis 12 49 69
Adult Dermatomyositis 49 55
Polymyositis with Skin Involvement 12
Dermatomyositis Sine Myositis 49
Adult Type Dermatomyositis 69
Dermatopolymyositis 12
Adm 49

Characteristics:

Orphanet epidemiological data:

55
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Dermatomyositis

NINDS : 50 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to childhood type dermatomyositis and antisynthetase syndrome, and has symptoms including chondrocalcinosis, dry skin and pruritus. An important gene associated with Dermatomyositis is IFIH1 (Interferon Induced With Helicase C Domain 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and tRNA Aminoacylation. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include muscle or, skin and lung, and related phenotype is mortality/aging.

NIH Rare Diseases : 49 Amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. Some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; Gottron's papules and heliotrope eyelids. Pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. While patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. Fatigue is reported in at least 50% of patients. Some cases have been associated with internal malignancy and/or interstitial lung disease. Treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (IV) immunoglobulin. Last updated: 1/10/2013

Disease Ontology : 12 A myositis that results_in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

Wikipedia : 72 Dermatomyositis (DM) is a long term inflammatory disorder which affects muscles. Its symptoms are... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 childhood type dermatomyositis 34.1 IFIH1 MORC3
2 antisynthetase syndrome 31.6 HARS KARS TARS
3 myositis 31.1 AARS CHKB HARS IFIH1 PIK3C2A TARS
4 interstitial lung disease 30.6 IFIH1 IL1A SFTPD
5 polymyositis 30.2 AARS CHKB GARS HARS IARS ICAM1
6 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 29.9 CHKB PIK3C2A
7 vasculitis 29.4 ICAM1 S100A9 VCAM1
8 oral lichen planus 29.1 ICAM1 IL1A VCAM1
9 adult dermatomyositis 12.2
10 neonatal dermatomyositis 12.0
11 complement component 9 deficiency 11.6
12 hypertension, essential 11.2
13 idiopathic inflammatory myopathy 11.2
14 juvenile polymyositis 11.2
15 cryptogenic organizing pneumonia 11.2
16 lung disease 10.5
17 calcinosis 10.4
18 creatine phosphokinase, elevated serum 10.2 CHKB PIK3C2A
19 lymphocytic vasculitis 10.2 ICAM1 VCAM1
20 lupus erythematosus 10.2
21 pneumonia 10.2
22 cortical thymoma 10.2 ICAM1 VCAM1
23 myopathy 10.1
24 arthritis 10.1
25 mooren's ulcer 10.1 ICAM1 VCAM1
26 inclusion body myositis 10.1
27 systemic lupus erythematosus 10.1
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
29 melanoma 10.1
30 dengue disease 10.1 ICAM1 PIK3C2A VCAM1
31 panniculitis 10.0
32 lymphoma 10.0
33 limbal stem cell deficiency 10.0 ICAM1 IL1A VCAM1
34 rheumatoid arthritis 10.0
35 autoinflammation, lipodystrophy, and dermatosis syndrome 9.9 ICAM1 IL1A VCAM1
36 juvenile overlap myositis 9.9
37 adenocarcinoma 9.9
38 cutaneous lupus erythematosus 9.9
39 charcot-marie-tooth disease 9.9 AARS GARS HARS KARS
40 scleroderma, familial progressive 9.9
41 nasopharyngeal carcinoma 9.8
42 skin disease 9.8
43 nasopharyngitis 9.8
44 multicentric reticulohistiocytosis 9.8
45 connective tissue disease 9.8
46 lipodystrophy 9.8
47 fasciitis 9.8
48 subendocardial myocardial infarction 9.8 ICAM1 VCAM1
49 pityriasis rubra pilaris 9.8
50 lung cancer 9.8

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

55 31 (show all 50)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chondrocalcinosis 55 31 frequent (33%) Frequent (79-30%) HP:0000934
2 dry skin 55 31 frequent (33%) Frequent (79-30%) HP:0000958
3 pruritus 55 31 frequent (33%) Frequent (79-30%) HP:0000989
4 cutaneous photosensitivity 55 31 occasional (7.5%) Occasional (29-5%) HP:0000992
5 acrocyanosis 55 31 frequent (33%) Frequent (79-30%) HP:0001063
6 muscular hypotonia 55 31 frequent (33%) Frequent (79-30%) HP:0001252
7 arthritis 55 31 frequent (33%) Frequent (79-30%) HP:0001369
8 abnormality of the nail 55 31 frequent (33%) Frequent (79-30%) HP:0001597
9 dysphonia 55 31 occasional (7.5%) Occasional (29-5%) HP:0001618
10 myocardial infarction 55 31 occasional (7.5%) Occasional (29-5%) HP:0001658
11 pericarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0001701
12 weight loss 55 31 frequent (33%) Frequent (79-30%) HP:0001824
13 abnormality of eosinophils 55 31 occasional (7.5%) Occasional (29-5%) HP:0001879
14 fever 55 31 occasional (7.5%) Occasional (29-5%) HP:0001945
15 pulmonary arterial hypertension 55 31 occasional (7.5%) Occasional (29-5%) HP:0002092
16 respiratory insufficiency 55 31 frequent (33%) Frequent (79-30%) HP:0002093
17 recurrent respiratory infections 55 31 frequent (33%) Frequent (79-30%) HP:0002205
18 pulmonary fibrosis 55 31 frequent (33%) Frequent (79-30%) HP:0002206
19 diffuse reticular or finely nodular infiltrations 55 31 frequent (33%) Frequent (79-30%) HP:0002207
20 vasculitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0002633
21 lymphoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0002665
22 arthralgia 55 31 frequent (33%) Frequent (79-30%) HP:0002829
23 autoimmunity 55 31 hallmark (90%) Very frequent (99-80%) HP:0002960
24 breast carcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0003002
25 myalgia 55 31 hallmark (90%) Very frequent (99-80%) HP:0003326
26 emg abnormality 55 31 hallmark (90%) Very frequent (99-80%) HP:0003457
27 proximal muscle weakness 55 31 hallmark (90%) Very frequent (99-80%) HP:0003701
28 interstitial pulmonary abnormality 55 31 frequent (33%) Frequent (79-30%) HP:0006530
29 aplasia/hypoplasia of the skin 55 31 occasional (7.5%) Occasional (29-5%) HP:0008065
30 feeding difficulties in infancy 55 31 occasional (7.5%) Occasional (29-5%) HP:0008872
31 inflammatory myopathy 55 31 hallmark (90%) Very frequent (99-80%) HP:0009071
32 erythema 55 31 hallmark (90%) Very frequent (99-80%) HP:0010783
33 abnormal hair quantity 55 31 frequent (33%) Frequent (79-30%) HP:0011362
34 sinus tachycardia 55 31 occasional (7.5%) Occasional (29-5%) HP:0011703
35 fatigue 55 31 frequent (33%) Frequent (79-30%) HP:0012378
36 myocarditis 55 31 occasional (7.5%) Occasional (29-5%) HP:0012819
37 lung adenocarcinoma 55 31 occasional (7.5%) Occasional (29-5%) HP:0030078
38 periorbital edema 55 31 hallmark (90%) Very frequent (99-80%) HP:0100539
39 telangiectasia of the skin 55 31 occasional (7.5%) Occasional (29-5%) HP:0100585
40 cellulitis 55 31 occasional (7.5%) Occasional (29-5%) HP:0100658
41 gastrointestinal stroma tumor 55 31 occasional (7.5%) Occasional (29-5%) HP:0100723
42 gangrene 55 31 occasional (7.5%) Occasional (29-5%) HP:0100758
43 papule 55 31 frequent (33%) Frequent (79-30%) HP:0200034
44 skin ulcer 55 31 frequent (33%) Frequent (79-30%) HP:0200042
45 abnormality of the eyelid 55 Very frequent (99-80%)
46 edema 55 Very frequent (99-80%)
47 abnormality of the voice 55 Occasional (29-5%)
48 neoplasm 55 Occasional (29-5%)
49 arrhythmia 55 Occasional (29-5%)
50 abnormal eyelid morphology 31 hallmark (90%) HP:0000492

UMLS symptoms related to Dermatomyositis:


pruritus, exanthema

MGI Mouse Phenotypes related to Dermatomyositis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 AARS CHD4 GARS ICAM1 IFIH1 KARS

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
3 Vaccines Phase 4
4 Adrenocorticotropic Hormone Phase 4,Phase 2
5 beta-endorphin Phase 4,Phase 2
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
9 Melanocyte-Stimulating Hormones Phase 4,Phase 2
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
17
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
18
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
22
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
23
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
24
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
25
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
26
Infliximab Approved Phase 2, Phase 3 170277-31-3
27
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
28
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
29
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
30
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
31
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
34 tannic acid Approved, Nutraceutical Phase 2, Phase 3
35 Antiemetics Phase 3,Phase 2
36 Antifungal Agents Phase 3,Phase 2
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2
39 Antimetabolites, Antineoplastic Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Autonomic Agents Phase 3,Phase 2
42 Calcineurin Inhibitors Phase 3,Phase 2
43 Cyclosporins Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 glucocorticoids Phase 3,Phase 2,Phase 1
48 Methylprednisolone acetate Phase 3,Phase 2
49 Methylprednisolone Hemisuccinate Phase 3,Phase 2
50 Neuroprotective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 85)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
6 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
9 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
10 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
11 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
12 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
13 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
15 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
16 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
17 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
18 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
19 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
20 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
21 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
22 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
23 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
24 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
25 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
26 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
27 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
28 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
29 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
30 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
31 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
32 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
33 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
34 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
35 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
36 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
37 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo;JBT-101 Open-label
38 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
39 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
40 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
41 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
42 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
43 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
44 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
45 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Completed NCT02780674 Phase 1
46 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
47 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
48 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1 Tofacitinib
49 Dermatomyositis and Polymyositis Registry Unknown status NCT01637064 Acthar
50 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomyositis:

18
Muscle Or

MalaCards organs/tissues related to Dermatomyositis:

38
Skin, Lung, Bone, T Cells, Heart, Colon, Testes

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 1353)
# Title Authors Year
1
Role of the chemokine receptors CXCR3, CXCR4 and CCR7 in the intramuscular recruitment of plasmacytoid dendritic cells in dermatomyositis. ( 29366593 )
2018
2
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. ( 29293605 )
2018
3
Increased risk of venous thromboembolism associated with polymyositis and dermatomyositis: a meta-analysis. ( 29416342 )
2018
4
The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease. ( 29325580 )
2018
5
Horizontal and vertical sections of scalp biopsy specimens from dermatomyositis patients with scalp involvement. ( 29409918 )
2018
6
Anti-aminoacyl tRNA Synthetase Antibody-Positive Clinically Amyopathic Dermatomyositis. ( 29346626 )
2018
7
Extensive skin ulcers in a child with juvenile dermatomyositis. ( 29367373 )
2018
8
Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. ( 29419471 )
2018
9
Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. ( 29361142 )
2018
10
Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. ( 29289262 )
2018
11
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. ( 29027009 )
2018
12
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. ( 29321815 )
2018
13
Dermatomyositis: Histopathologic findings of parakeratosis and dermal edema revisited. ( 29330862 )
2018
14
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. ( 28993346 )
2018
15
Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study. ( 29419464 )
2018
16
Splicing variant of<i>WDFY4</i>augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. ( 29331962 )
2018
17
Ground-glass opacity heralding invasive lung adenocarcinoma with prodromal dermatomyositis: a case report. ( 29415746 )
2018
18
Bosentan for Cutaneous Ulcers in Anti-MDA5 Dermatomyositis. ( 29344607 )
2018
19
Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. ( 29373707 )
2018
20
Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report. ( 29338781 )
2018
21
Anti-transcription intermediary factor 1I^ antibody titer correlates with clinical symptoms in a patient with recurrent dermatomyositis associated with ovarian cancer. ( 29341447 )
2018
22
Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling. ( 29342499 )
2018
23
Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption. ( 29346706 )
2018
24
A case of dermatomyositis presenting with inverse Gottron's papules as the first manifestation. ( 29400296 )
2018
25
Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin? ( 29424763 )
2018
26
Dermatomyositis: clinicopathological correlations. ( 29368856 )
2018
27
Paraneoplastic Dermatomyositis Syndrome Presenting as Dysphagia. ( 28912913 )
2017
28
Juvenile Dermatomyositis: Key Roles of Muscle Magnetic Resonance Imaging and Early Aggressive Treatment. ( 28911766 )
2017
29
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis. ( 27803134 )
2017
30
A case of lipoatrophic diabetes induced by juvenile dermatomyositis. ( 28895299 )
2017
31
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
32
Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. ( 29237618 )
2017
33
Pyruvate kinase M2 and the mitochondrial ATPase Inhibitory Factor 1 provide novel biomarkers of dermatomyositis: a metabolic link to oncogenesis. ( 28183315 )
2017
34
Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. ( 28490218 )
2017
35
Potential role of autophagy in Ta89cell survival in polymyositis and dermatomyositis. ( 28586060 )
2017
36
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
37
Pleurisy Caused by Mycobacterium abscessus in a Young Patient with Dermatomyositis: A Case Report and Brief Review of the Literature. ( 29269658 )
2017
38
Paraneoplastic Dermatomyositis. ( 28457044 )
2017
39
Life-threatening systemic capillary leak syndrome in juvenile dermatomyositis. ( 28957546 )
2017
40
Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. ( 28842784 )
2017
41
T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis. ( 29172719 )
2017
42
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
43
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. ( 28488124 )
2017
44
Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1I^ antibody-positive dermatomyositis. ( 28884788 )
2017
45
Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia. ( 28045754 )
2017
46
Race and income affects outcomes in juvenile dermatomyositis. ( 28434566 )
2017
47
Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. ( 28460448 )
2017
48
Image Gallery: Palmoplantar hyperkeratosis in dermatomyositis with anti-PM/Scl antibodies. ( 28504398 )
2017
49
Quinacrine Suppresses Tumor Necrosis Factor-I+ and IFN-I+ in Dermatomyositis andA Cutaneous Lupus Erythematosus. ( 28941496 )
2017
50
Clinical and Dermoscopic Features of the Scalp in 31 Patients with Dermatomyositis. ( 28879187 )
2017

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 AARS C9 GARS IARS ICAM1 PIK3C2A
2 cytosol GO:0005829 9.77 AARS C9 CHKB GARS HARS IARS
3 cytoplasm GO:0005737 9.5 AARS CHD3 CHD4 GARS HARS IARS
4 NuRD complex GO:0016581 9.32 CHD3 CHD4
5 aminoacyl-tRNA synthetase multienzyme complex GO:0017101 9.26 IARS KARS

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.85 C9 IFIH1 MX1 S100A9 SFTPD
2 immune system process GO:0002376 9.8 C9 IFIH1 MX1 S100A9 SFTPD
3 viral process GO:0016032 9.72 ICAM1 IFIH1 KARS MORC3 VCAM1
4 response to copper ion GO:0046688 9.49 ICAM1 IL1A
5 regulation of translational fidelity GO:0006450 9.48 AARS IARS
6 tRNA aminoacylation GO:0043039 9.43 AARS TARS
7 translation GO:0006412 9.43 AARS GARS HARS IARS KARS TARS
8 aminoacyl-tRNA metabolism involved in translational fidelity GO:0106074 9.37 AARS IARS
9 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
10 diadenosine tetraphosphate biosynthetic process GO:0015966 9.16 GARS KARS
11 tRNA aminoacylation for protein translation GO:0006418 9.1 AARS GARS HARS IARS KARS TARS

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 GARS HARS IFIH1 KARS MX1 SFTPD
2 ATP binding GO:0005524 9.9 AARS CHD3 CHD4 CHKB GARS HARS
3 zinc ion binding GO:0008270 9.85 CHD3 CHD4 IFIH1 MORC3 S100A9 UTRN
4 nucleotide binding GO:0000166 9.72 AARS CHD4 IARS KARS TARS
5 integrin binding GO:0005178 9.61 ICAM1 UTRN VCAM1
6 tRNA binding GO:0000049 9.56 AARS IARS KARS TARS
7 amino acid binding GO:0016597 9.46 AARS KARS
8 ligase activity GO:0016874 9.43 AARS GARS HARS IARS KARS TARS
9 aminoacyl-tRNA editing activity GO:0002161 9.4 AARS IARS
10 aminoacyl-tRNA ligase activity GO:0004812 9.1 AARS GARS HARS IARS KARS TARS

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....